ArticleFrontiers in pharmacology2026
Angelica sinensis polysaccharide inhibits pyroptosis and improves osteoarthritis through the collaborative power of PPARγ and Nrf2.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Osteoarthritis (OA) is an inflammatory disease, and pyroptosis causes a local inflammatory microenvironment that leads to chondrocyte disorder. This article aims to show that angelica sinensis polysaccharide (ASP) can improve the antioxidant and anti-inflammatory capacity of chondrocytes through the collaborative power of PPARγ and Nrf2, downregulate pyroptosis, and thus alleviate OA. Methods: After analyzing the clinical samples, the therapeutic effect of ASP was assessed Results: The expression of the NLRP3 inflammasome in OA cartilage was increased, and inflammatory cytokines were higher in OA serum. LPS promoted oxidative stress and induced pyroptosis in chondrocytes, while ASP mediated the collaborative power of PPARγ and Nrf2 to improve the viability of chondrocytes, reduce the activity of the NLRP3 inflammasome, and inhibit pyroptosis. Conclusion: These findings revealed the process of pyroptosis in chondrocytes and the enhancement of PPARγ and Nrf2 by ASP, which deepens our understanding of OA pathogenesis and could provide new insights for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.